Body Mass Index Quantitative Trait Locus 19 (BMIQ19)

Categories: Bone diseases, Endocrine diseases, Genetic diseases, Metabolic diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Body Mass Index Quantitative Trait Locus 19

MalaCards integrated aliases for Body Mass Index Quantitative Trait Locus 19:

Name: Body Mass Index Quantitative Trait Locus 19 57 28 5
Obesity 57 71
{obesity, Susceptibility to, Bmiq19} 38
Obesity, Susceptibility to, Bmiq19 57
Obesity, Susceptibility to 57
Obesity Bmiq19 57
Bmiq19 57



Autosomal recessive 57


57 (Updated 08-Dec-2022)
onset of hyperphagia reported between 6 months and 2 years of age
the oldest reported patient underwent menarche at age 14 years but had no subsequent menstrual cycles


Summaries for Body Mass Index Quantitative Trait Locus 19

OMIM®: 57 Patients with biallelic mutations in the ADCY3 gene show hyperphagia within the first 2 years of life and develop severe obesity. Other features include hyposmia or anosmia, and some patients exhibit mild to moderate intellectual disability (Saeed et al., 2018). (617885) (Updated 08-Dec-2022)

MalaCards based summary: Body Mass Index Quantitative Trait Locus 19, also known as obesity, is related to body mass index quantitative trait locus 11 and leptin deficiency or dysfunction, and has symptoms including symptoms, high weight and obesity, metabolically benign. An important gene associated with Body Mass Index Quantitative Trait Locus 19 is ADCY3 (Adenylate Cyclase 3). The drugs Vildagliptin and Lactitol have been mentioned in the context of this disorder. Affiliated tissues include skeletal muscle, liver and brain, and related phenotypes are intellectual disability and hypertriglyceridemia

Related Diseases for Body Mass Index Quantitative Trait Locus 19

Diseases in the Body Mass Index Quantitative Trait Locus 11 family:

Body Mass Index Quantitative Trait Locus 9 Body Mass Index Quantitative Trait Locus 8
Body Mass Index Quantitative Trait Locus 1 Body Mass Index Quantitative Trait Locus 2
Body Mass Index Quantitative Trait Locus 3 Body Mass Index Quantitative Trait Locus 4
Body Mass Index Quantitative Trait Locus 10 Body Mass Index Quantitative Trait Locus 7
Body Mass Index Quantitative Trait Locus 5 Body Mass Index Quantitative Trait Locus 6
Body Mass Index Quantitative Trait Locus 12 Body Mass Index Quantitative Trait Locus 13
Body Mass Index Quantitative Trait Locus 14 Body Mass Index Quantitative Trait Locus 15
Body Mass Index Quantitative Trait Locus 18 Body Mass Index Quantitative Trait Locus 19
Body Mass Index Quantitative Trait Locus 20

Diseases related to Body Mass Index Quantitative Trait Locus 19 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2456)
# Related Disease Score Top Affiliating Genes
1 body mass index quantitative trait locus 11 32.3 CENPO ADCY3
2 leptin deficiency or dysfunction 11.9
3 body mass index quantitative trait locus 20 11.9
4 body mass index quantitative trait locus 8 11.9
5 body mass index quantitative trait locus 12 11.9
6 body mass index quantitative trait locus 14 11.9
7 body mass index quantitative trait locus 4 11.9
8 body mass index quantitative trait locus 9 11.8
9 body mass index quantitative trait locus 7 11.8
10 body mass index quantitative trait locus 18 11.8
11 body mass index quantitative trait locus 10 11.8
12 leptin receptor deficiency 11.8
13 abdominal obesity-metabolic syndrome 1 11.6
14 obesity, early-onset, with adrenal insufficiency and red hair 11.6
15 obesity-hypoventilation syndrome 11.6
16 intellectual developmental disorder, x-linked, syndromic, wilson-turner type 11.5
17 cohen syndrome 11.5
18 abdominal obesity-metabolic syndrome 3 11.5
19 mehmo syndrome 11.5
20 proprotein convertase 1/3 deficiency 11.5
21 abdominal obesity-metabolic syndrome 4 11.5
22 mental retardation, truncal obesity, retinal dystrophy, and micropenis syndrome 11.5
23 morbid obesity and spermatogenic failure 11.5
24 abdominal obesity-metabolic syndrome quantitative trait locus 2 11.4
25 momo syndrome 11.4
26 type 2 diabetes mellitus 11.4
27 chops syndrome 11.4
28 spastic paraplegia, intellectual disability, nystagmus, and obesity 11.4
29 coenzyme q10 deficiency, primary, 2 11.4
30 chung-jansen syndrome 11.4
31 obesity, hyperphagia, and developmental delay 11.4
32 retinal dystrophy and obesity 11.3
33 non-alcoholic fatty liver disease 11.3
34 hypothalamic obesity 11.3
35 fatty liver disease 11.3
36 hydrocephalus obesity hypogonadism 11.3
37 obesity due to sim1 deficiency 11.3
38 coloboma-obesity-hypogenitalism-mental retardation syndrome 11.3
39 aniridia - ptosis - intellectual disability - familial obesity 11.3
40 rohhad 11.3
41 rapid-onset childhood obesity-hypothalamic dysfunction-hypoventilation-autonomic dysregulation syndrome 11.3
42 prader-willi syndrome 11.3
43 prediabetes syndrome 11.3
44 severe early-onset obesity-insulin resistance syndrome due to sh2b1 deficiency 11.3
45 camera-marugo-cohen syndrome 11.2
46 wilms tumor, aniridia, genitourinary anomalies, mental retardation, and obesity syndrome 11.2
47 mental retardation, obesity, mandibular prognathism, and eye and skin anomalies 11.2
48 ayazi syndrome 11.2
49 glucose intolerance 11.2
50 short stature, brachydactyly, impaired intellectual development, and seizures 11.2

Graphical network of the top 20 diseases related to Body Mass Index Quantitative Trait Locus 19:

Diseases related to Body Mass Index Quantitative Trait Locus 19

Symptoms & Phenotypes for Body Mass Index Quantitative Trait Locus 19

Human phenotypes related to Body Mass Index Quantitative Trait Locus 19:

30 (show all 9)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 intellectual disability 30 Very rare (1%) HP:0001249
2 hypertriglyceridemia 30 Very rare (1%) HP:0002155
3 obesity 30 Very rare (1%) HP:0001513
4 hyperinsulinemia 30 Very rare (1%) HP:0000842
5 anosmia 30 Very rare (1%) HP:0000458
6 hyposmia 30 Very rare (1%) HP:0004409
7 insulin resistance 30 Very rare (1%) HP:0000855
8 polyphagia 30 Very rare (1%) HP:0002591
9 increased serum leptin 30 Very rare (1%) HP:0031793

Symptoms via clinical synopsis from OMIM®:

57 (Updated 08-Dec-2022)
Laboratory Abnormalities:

Endocrine Features:
insulin resistance
elevated insulin levels
elevated leptin levels
elevated cortisol levels

Abdomen Gastrointestinal:
hyperphagia, early-onset

Neurologic Central Nervous System:
intellectual disability, mild to moderate (in some patients)

Head And Neck Nose:

Growth Weight:
obesity, early-onset

Neurologic Behavioral Psychiatric Manifestations:
hyperphagia, early-onset

Clinical features from OMIM®:

617885 (Updated 08-Dec-2022)

UMLS symptoms related to Body Mass Index Quantitative Trait Locus 19:

symptoms; high weight; obesity, metabolically benign; monogenic obesity

Drugs & Therapeutics for Body Mass Index Quantitative Trait Locus 19

Drugs for Body Mass Index Quantitative Trait Locus 19 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 934)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
Lactitol Approved, Investigational Phase 4 585-86-4 157355
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6 9578005
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
Indapamide Approved Phase 4 26807-65-8 3702
Insulin lispro Approved Phase 4 133107-64-9 16132438
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560
Insulin aspart Approved Phase 4 116094-23-6 16132418
Hydroxychloroquine Approved Phase 4 118-42-3 3652
Metyrapone Approved, Investigational Phase 4 54-36-4 4174
Cyproterone acetate Approved, Investigational Phase 4 427-51-0 9880
Tolnaftate Approved, Investigational, Vet_approved Phase 4 2398-96-1 5510
Phentermine Approved, Illicit Phase 4 122-09-8 4771
Rosiglitazone Approved, Investigational Phase 4 122320-73-4, 155141-29-0 77999
Coal tar Approved Phase 4 8007-45-2
Loperamide Approved Phase 4 53179-11-6 3955
Heparin, bovine Approved, Investigational, Withdrawn Phase 4 9005-49-6 22833565 9812414 772
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
Calcium carbonate Approved, Investigational Phase 4 471-34-1
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
22 Tomato Approved Phase 4
Dapagliflozin Approved Phase 4 461432-26-8 9887712
Infliximab Approved Phase 4 170277-31-3
Octreotide Approved, Investigational Phase 4 83150-76-9 383414 6400441
Saxagliptin Approved Phase 4 361442-04-8 11243969
Ethinylestradiol Approved Phase 4 57-63-6 5991
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
Moxifloxacin Approved, Investigational Phase 4 186826-86-8, 354812-41-2, 151096-09-2 152946
Desflurane Approved Phase 4 57041-67-5 42113
Zonisamide Approved, Investigational Phase 4 68291-97-4 5734
Apixaban Approved Phase 4 503612-47-3 10182969
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6
34 Orange Approved Phase 4
Drospirenone Approved Phase 4 67392-87-4 68873
Glyburide Approved Phase 4 10238-21-8 3488
Atorvastatin Approved Phase 4 134523-00-5 60823
Risedronic acid Approved, Investigational Phase 4 105462-24-6 5245
Memantine Approved, Investigational Phase 4 41100-52-1, 19982-08-2 4054
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
Letrozole Approved, Investigational Phase 4 112809-51-5 3902
Galantamine Approved Phase 4 357-70-0, 1953-04-4 9651
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
Anidulafungin Approved, Investigational Phase 4 166663-25-8 166548
Chenodeoxycholic acid Approved Phase 4 474-25-9 10133
Bismuth subsalicylate Approved, Vet_approved Phase 4 14882-18-9 53629521 16682734
Clarithromycin Approved Phase 4 81103-11-9 84029
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
Nadroparin Approved, Investigational Phase 4
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456 5824

Interventional clinical trials:

(show top 50) (show all 8962)
# Name Status NCT ID Phase Drugs
1 Evaluation of the Effects of Laying Early (Between 12 and 16) a Gastric Band on the Prevention of Morbid Obesity in Late Adolescence. Randomized Checked Against Standard Management of Obesity in This Population. Unknown status NCT01700738 Phase 4
2 Prevention and Control of Obesity in Primary School Children in Tehran Unknown status NCT02082080 Phase 4
3 A Study of the Pharmacokinetics of Dexmedetomidine in Morbid Obesity. Unknown status NCT01864187 Phase 4 Dexmedetomidine
4 The Effect of Moxonidine and Regression of Early Target Organ Damage in Young Subjects With Abdominal Obesity and Hypertension: a Randomised, Double Blind, Active Comparator Clinical Trial Unknown status NCT01360710 Phase 4 Moxonidine;Irbesartan
5 Effect of Acarbose and Vildagliptin on Visceral Fat Distribution in Overweight and Obesity Patients With Newly Diagnosed Type 2 Diabetes Mellitus: A Randomized Control Study Unknown status NCT02999841 Phase 4 Acarbose;Vildagliptin
6 Effect of Saxagliptin on Body Fat , Glucose and Beta Cell Function in Patients With Newly Diagnosed Pre-Diabetes Mellitus and Obesity Unknown status NCT01960205 Phase 4 Saxagliptin;saxagliptin;metformin
7 The Therapeutic Effect of Catgut Embedding in Obesity-A Randomized, Double-blind, Placebo-controlled Clinical Trial Unknown status NCT02276235 Phase 4
8 Trial Evaluating Effectiveness of Contrave (Naltrexone HCl / Bupropion HCl) for Weight Maintenance in Adults With BMI ≥ 27 Kg/m2, After 6 Month Intensive Behavior Modification Program: Contrave Obesity Trials (COR) Weight Maintenance Study Unknown status NCT04589130 Phase 4 Contrave 8Mg-90Mg Extended-Release Tablet;Placebo
9 Comparing Dexlansoprazole With Double-dose Lansoprazole to Achieve Sustained Symptomatic Response in Overweight and Obesity Patients With Reflux Esophagitis in Los Angeles Grades A & B Unknown status NCT02759393 Phase 4 Dexlansoprazole;Lansoprazole
10 The Effect of Obesity in Dexmedetomidine Metabolic Clearance Unknown status NCT02557867 Phase 4 Dexmedetomidine
11 Treatment of Obesity With Topiramate in Patients With Polycystic Ovary Syndrome: a Double-blind Placebo-controlled Clinical Trial Unknown status NCT04453306 Phase 4 Topiramate;Placebo
12 Effect and Safety of Benaglutide or Metformin in Patients With Simple Obesity Who Have Inadequate Weight Control :A Randomized, Open, Controlled and Single-site Clinical Trail Unknown status NCT03593668 Phase 4 Metformin;Benaglutide
13 Double-blind Randomized Trial Using Oral Metformin Versus Placebo in the Treatment of Acanthosis Nigricans in Children With Obesity Unknown status NCT02438020 Phase 4 Metformin
14 Assessment of the Effect of Moxonidine and Diet on Cardiac, Renal and Endothelial Function in Young Subjects With Abdominal Obesity Unknown status NCT01180231 Phase 4 Moxonidine (Physiotens)
15 Correlation of Postoperative VAS Values and Body Mass Index in Patients Undergoing Abdominal Surgery: A Clinical Trial Unknown status NCT02017314 Phase 4 Morphine
16 Prospective Randomized Study of Effects of Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Sleeve Gastrectomy Unknown status NCT00667706 Phase 4
17 Laparoscopic Non Banded Vertical (Magenstrasse and Mill) Gastroplasty In Bariatric Surgery. Morbidity and Results on Weight Loss and Associated Co-morbidities Unknown status NCT02050477 Phase 4
18 Comparing the Efficacy of Two Frequently Used Doses of Enoxaparin for VTE Prophylaxis After Bariatric Surgery Unknown status NCT01970202 Phase 4 40mg Enoxaparin;60mg Enoxaparin
19 Effect of Docosahexaenoic Acid Supplementation on Microbiome in Obese ChiLdrEn. The DAMOCLE Study Unknown status NCT04151758 Phase 4 Docosahexaenoic Acid Supplementation
20 Laparoscopic Bariatric Surgery: Impact of the Level of Neuromuscular Blockade on Surgical Conditions - Comparison Between Moderate and Deep Neuromuscular Blockade Unknown status NCT02118844 Phase 4 rocuronium
21 Preoperative Carbohydrate Loading in Bariatric Surgery - Randomized Clinical Trail Unknown status NCT04486079 Phase 4
22 Effect of POSTbiotics Supplementation on Microbiome in OBese Children: the POST-OB Study Unknown status NCT04151823 Phase 4 Vitamin D3;Immunofos
23 Prospective, Pharmacokinetic Study for Determination of the Relationship Between Lean Body Weight and Anti-Xa Activity 4 Hours After Subcutaneous Injection of 5700 IU Nadroparin in Morbidly Obese Patients After Bariatric Surgery. Unknown status NCT02295150 Phase 4 Nadroparin
24 Gut Hormones as Mediators of Different Weight Loss Responses After Roux-en-Y Gastric Bypass Unknown status NCT02374632 Phase 4
25 Could Gut Microbiome Contribute to the Therapeutic Effect of Liraglutide 3.0 mg? A Randomized Double Blind Placebo Controlled Trial Unknown status NCT04046822 Phase 4 Liraglutide 6 MG/ML [Saxenda];Placebo
26 Healthy Opportunities for Physical Activity and Nutrition (HOP'N) After-School Project Unknown status NCT01015599 Phase 4
27 Laparoscopic Roux-en-Y Gastric Bypass vs. Laparoscopic BPD-Duodenal Switch for Superobesity (BMI > 50 kg/m2)- A Randomized Clinical Trial Unknown status NCT00327912 Phase 4
28 International, Multi Centre, Open, Prospective, Randomized Study: Banded Versus Conventional Laparoscopic Roux-en-Y (GABY) Unknown status NCT01015469 Phase 4
29 The Effect of Vitamin A Supplementation on CD4+ T-cell Secretion in Obese Individuals Unknown status NCT01405352 Phase 4
30 Levonorgestrel-releasing Intrauterine Device Effects on Hemostatic and Arterial Function of Obese Women Unknown status NCT01320917 Phase 4
31 Endobarrier Treatment in Obese Subjects With T2DM Unknown status NCT01718457 Phase 4
32 Structured Exerise Training in Infertile Obese Patients Treated With Assisted Reproductive Techniques: a Randomized Controlled Trial Unknown status NCT01892111 Phase 4
33 Efficacy and Safety of Liraglutide-bolus (Liraglutide Plus Prandial Insulin) Versus Glargine-bolus Therapy in Overweight / Obese Patients With Uncontrolled Type 2 Diabetes (LiraGooD)--A Multicenter Randomized Controlled Study Unknown status NCT03087032 Phase 4 Liraglutide;insulin glargine
34 Effects of Valsartan on Metabolic Syndrome in Patients With Hypertension Unknown status NCT00790946 Phase 4 Valsartan
35 Evaluation of Family Intervention Program for the Treatment of Overweight or Obese Children (Nereu Program): Randomized Clinical Trial Unknown status NCT01878994 Phase 4
36 Influence of Erythromycin on ad Libitum Food Intake and the Evaluation of Motilin in Food Timing in Healthy Volunteers and Patients Unknown status NCT03024879 Phase 4 Erythromycin;Saline
37 Study of Metabolic Effects of EndoBarrier Versus Intragastric Balloon in Obese Patients With Type 2 Diabetes. Unknown status NCT01848795 Phase 4
38 Beijing Chao-yang Hospital, Capital Medical University Unknown status NCT02583438 Phase 4 Saxagliptin (Bristol-Myers Squibb Company)
39 A 24-Week, National, Single-Centre, Open-Labelled, Randomised, Parallel-Group Trial Comparing Energy Expenditure With Insulin Detemir Versus NPH Insulin Using a Basal-Bolus Regimen With Insulin Aspart as the Mealtime Insulin in Subjects With Type 2 Diabetes Unknown status NCT00788840 Phase 4 Insulatard;Detemir
40 Randomisation to Endoluminal Intestinal Liner Alone Versus With Incretin Analogue in SustainEd Diabesity (REVISE-Diabesity) Unknown status NCT02055014 Phase 4 Liraglutide
41 Synergy Effect of the Appetite Hormone GLP-1 (LiragluTide) and Exercise on Maintenance of Weight Loss and Health After a Low Calorie Diet - the S-LiTE Randomized Trial Unknown status NCT04122716 Phase 4 Liraglutide
42 The Efficacy of a Once Weekly Glucagon-Like Peptide-1 Agonist on Body Weight/Composition and Metabolic Parameters in Persons With SCI Unknown status NCT03292315 Phase 4 Exenatide 2 MG Injection [Bydureon]
43 The Effect of Mirabegron on Brown Adipose Tissue in Healthy Young White Caucasian and South Asian Men Unknown status NCT03012113 Phase 4 Mirabegron;Placebo Oral Capsule
44 The Effect of Exenatide on Brown Adipose Tissue Activity and Energy Expenditure in Healthy Young Men Unknown status NCT03002675 Phase 4 Bydureon
45 Sildenafil Activates Browning of White Adipose and Improves Insulin Sensitivity in Human Adults Unknown status NCT02524184 Phase 4 sildenafil;placebo
46 The Effect of Hydroxychloroquine Sulphate on Hedonic Food Intake, Appetite-related Sensations and Gastrointestinal Hormone Release in Overweight Female Subjects Unknown status NCT04005781 Phase 4 Hydroxychloroquine sulphate;Placebo
47 The Effect of Hydroxychloroquine Sulphate on Hedonic Food Intake, Appetite-related Sensations and Gastrointestinal Hormone Release in Healthy Female Subjects Unknown status NCT04005768 Phase 4 Hydroxychloroquine Sulphate;Placebo
48 Metformin Treatment for Preventing Gestational Diabetes in High-risk Patients Unknown status NCT00883259 Phase 4 Metformin
49 The Effects of Cortisol Blockade on Nutritional Sympathetic Nervous System Responsiveness in Overweight and Obese Subjects With Metabolic Syndrome Unknown status NCT01620684 Phase 4 metyrapone;placebo
50 A Pilot Study: Comparing Physiological Parameters and Outcome Variables Using Pressure Support Ventilation Versus Pressure Controlled Ventilation in Patients With Chronic Respiratory Failure Unknown status NCT00994552 Phase 4

Search NIH Clinical Center for Body Mass Index Quantitative Trait Locus 19

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Benzphetamine hydrochloride
Dexfenfluramine Hydrochloride
Diethylpropion Hydrochloride
Fenfluramine Hydrochloride
lorcaserin hydrochloride
phendimetrazine tartrate
Phenmetrazine Hydrochloride
Phentermine Hydrochloride
Phenylpropanolamine Hydrochloride

Genetic Tests for Body Mass Index Quantitative Trait Locus 19

Genetic tests related to Body Mass Index Quantitative Trait Locus 19:

# Genetic test Affiliating Genes
1 Body Mass Index Quantitative Trait Locus 19 28 ADCY3

Anatomical Context for Body Mass Index Quantitative Trait Locus 19

Organs/tissues related to Body Mass Index Quantitative Trait Locus 19:

MalaCards : Skeletal Muscle, Liver, Brain, Adipocyte, Heart, Breast, Endothelial

Publications for Body Mass Index Quantitative Trait Locus 19

Articles related to Body Mass Index Quantitative Trait Locus 19:

(show top 50) (show all 30004)
# Title Authors PMID Year
Loss-of-function variants in ADCY3 increase risk of obesity and type 2 diabetes. 62 57 5
29311636 2018
Loss-of-function mutations in ADCY3 cause monogenic severe obesity. 62 57 5
29311637 2018
Genome-wide association study of height-adjusted BMI in childhood identifies functional variant in ADCY3. 57
25044758 2014
Addiction-like behaviour towards high-fat high-sugar food predicts relapse propensity in both obesity prone and obesity resistant C57BL/6 J mice. 62
36209772 2023
Ultra-processed food consumption and adult obesity risk: a systematic review and dose-response meta-analysis. 62
34190668 2023
Impact of Age on Obesity-related Comorbidity After Gastric Bypass: A Cohort Study From the Scandinavian Obesity Surgery Registry (SOReg). 62
33856387 2022
Obstacles and Opportunities in Managing Coexisting Obesity and CKD: Report of a Scientific Workshop Cosponsored by the National Kidney Foundation and The Obesity Society. 62
36280397 2022
Obstacles and opportunities in managing coexisting obesity and CKD: Report of a scientific workshop cosponsored by the National Kidney Foundation and The Obesity Society. 62
36268562 2022
Gut Microbiome and Its Impact on Obesity and Obesity-Related Disorders. 62
36469257 2022
Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity Federation. 62
36007112 2022
Relationship Between Moderate-to-Vigorous Physical Activity and Glycemia Among Young Adults with Type 1 Diabetes and Overweight or Obesity: Results from the Advancing Care for Type 1 Diabetes and Obesity Network (ACT1ON) Study. 62
35984327 2022
The impact of obesity on the outcome of severe SARS-CoV-2 ARDS in a high volume ECMO centre: ECMO and corticosteroids support the obesity paradox. 62
36219946 2022
Impairment of gut microbial biotin metabolism and host biotin status in severe obesity: effect of biotin and prebiotic supplementation on improved metabolism. 62
35017197 2022
Nutritional management of individuals with obesity and COVID-19: ESPEN expert statements and practical guidance. 62
34140163 2022
Obesity and dietary fat influence dopamine neurotransmission: exploring the convergence of metabolic state, physiological stress, and inflammation on dopaminergic control of food intake. 62
34184629 2022
Genotype frequencies and the Hardy-Weinberg equilibrium on rs9939609 FTO and rs17782313 MC4R: Implications for statistical associations to overweight and obesity in children and adolescents (re. "Polymorphisms on rs9939609 FTO and rs17782313 MC4R genes in children and adolescent obesity: a systematic review"). 62
35835628 2022
Secreted EMC10 is upregulated in human obesity and its neutralizing antibody prevents diet-induced obesity in mice. 62
36443308 2022
Targeted dietary approaches for the management of obesity and severe obesity in children and adolescents: A systematic review and meta-analysis. 62
36394356 2022
Improving applicability of the new obesity classification based on weight history in severe obesity. 62
36394489 2022
European Association for the Study of Obesity (EASO) position statement on medical nutrition therapy for the management of overweight and obesity in children and adolescents developed in collaboration with the European Federation of the Associations of Dietitians (EFAD). 62
36349767 2022
Reliable Knowledge about Obesity Risk, Rather Than Personality, Is Associated with Positive Beliefs towards Obese People: Investigating Attitudes and Beliefs about Obesity, and Validating the Polish Versions of ATOP, BAOP and ORK-10 Scales. 62
36429694 2022
A Rapid Review of the Impact of Family-Based Digital Interventions for Obesity Prevention and Treatment on Obesity-Related Outcomes in Primary School-Aged Children. 62
36432522 2022
Bifidobacterium bifidum DS0908 and Bifidobacterium longum DS0950 CultureSupernatants Ameliorate Obesity-Related Characteristics in Mice with High-Fat DietInduced Obesity. 62
36457182 2022
Differential regulation of nucleus accumbens glutamate and GABA in obesity-prone and obesity-resistant rats. 62
36336816 2022
Re-evaluating obesity in Mexico-lessons for the global obesity epidemic. 62
36442500 2022
Deciphering the "obesity paradox" in the elderly: A systematic review and meta-analysis of sarcopenic obesity. 62
36443946 2022
The HIF1α polymorphism rs2301104 is associated with obesity and obesity-related cytokines in Han Chinese population. 62
36422747 2022
Antioxidant, Anti-Obesity, and Hypolipidemic Effects of Polyphenol Rich Star Anise (Illicium verum) Tea in High-Fat-Sugar Diet-Induced Obesity Rat Model. 62
36421427 2022
Support needs of people living with obesity during transition from tertiary obesity treatment to community care. 62
36207249 2022
Famine exposure in adolescence is associated with a higher risk of overweight/obesity and abdominal obesity in adulthood: A meta-analysis. 62
36215886 2022
The obesity paradox: Retinopathy, obesity, and circulating risk markers in youth with type 2 diabetes in the TODAY Study. 62
36150365 2022
Association of environmental exposure to perchlorate, nitrate, and thiocyanate with overweight/obesity and central obesity among children and adolescents in the United States of America using data from the National Health and Nutrition Examination Survey (NHANES) 2005-2016. 62
36251327 2022
Gender-specific factors contributing to visceral obesity including the sleep-obesity relationship: a large-scale cross-sectional study from East Asia. 62
36434061 2022
Changes in obesity and iron deficiency between 4 and 9 years of age. Longitudinal study of childhood obesity (ELOIN). 62
35931811 2022
Sarcopaenia, obesity, sarcopaenic obesity and outcomes following hepatic resection for colorectal liver metastases: a systematic review and meta-analysis. 62
35922276 2022
Sex differences in the association of physical activity levels and vitamin D with obesity, sarcopenia, and sarcopenic obesity: a cross-sectional study. 62
36434519 2022
The founding of Obesity Research/Obesity: A brief history. 62
36321280 2022
The use of virtual visits for obesity pharmacotherapy in patients with overweight or obesity compared with in-person encounters. 62
36156456 2022
Fatty Liver/Adipose Tissue Dual-Targeting Nanoparticles with Heme Oxygenase-1 Inducer for Amelioration of Obesity, Obesity-Induced Type 2 Diabetes, and Steatohepatitis. 62
36209391 2022
Assessment of Overweight, Obesity, Central Obesity, and Type 2 Diabetes among Adolescents in Qatar: A Cross-Sectional Study. 62
36361482 2022
A hint for the obesity paradox and the link between obesity, perirenal adipose tissue and Renal Cell Carcinoma progression. 62
36402906 2022
The promise of new anti-obesity therapies arising from knowledge of genetic obesity traits. 62
35902734 2022
Butyrate to combat obesity and obesity-associated metabolic disorders: Current status and future implications for therapeutic use. 62
35856338 2022
Intentional weight loss reduces cancer risk and mortality: New studies suggest that bariatric surgery can make a difference in risk and mortality reduction for obesity-related cancer types: New studies suggest that bariatric surgery can make a difference in risk and mortality reduction for obesity-related cancer types. 62
36161430 2022
Several areas of overlap between obesity and aging indicate obesity as a biomarker of accelerated aging of human B cell function and antibody responses. 62
36289515 2022
HPA Axis Responsiveness Associates with Central Serotonin Transporter Availability in Human Obesity and Non-Obesity Controls. 62
36358358 2022
Possible mediators of metabolic endotoxemia in women with obesity and women with obesity-diabetes in The Gambia. 62
35933445 2022
Sarcopenic Obesity Is Associated With Reduced Cardiorespiratory Fitness Compared With Nonsarcopenic Obesity in Patients With Heart Failure With Reduced Ejection Fraction. 62
36098058 2022
The Anti-Obesity Potential of Superparamagnetic Iron Oxide Nanoparticles against High-Fat Diet-Induced Obesity in Rats: Possible Involvement of Mitochondrial Biogenesis in the Adipose Tissues. 62
36297569 2022
Daytime sleepiness, addictive-like eating, and obesity sequelae in Black and African American youth with obesity. 62
36274028 2022

Variations for Body Mass Index Quantitative Trait Locus 19

ClinVar genetic disease variations for Body Mass Index Quantitative Trait Locus 19:

# Gene Name Type Significance ClinVarId dbSNP ID Position
1 ADCY3, CENPO NM_004036.5(ADCY3):c.3315del (p.Ile1106fs) DEL Risk Factor
495044 rs1553329804 GRCh37: 2:25042921-25042921
GRCh38: 2:24820052-24820052
2 ADCY3, CENPO NM_004036.5(ADCY3):c.3348CTT[2] (p.Phe1118del) MICROSAT Risk Factor
495047 rs750852737 GRCh37: 2:25042880-25042882
GRCh38: 2:24820011-24820013
3 ADCY3 NM_004036.5(ADCY3):c.1268del (p.Gly423fs) DEL Risk Factor
495045 rs754914420 GRCh37: 2:25062829-25062829
GRCh38: 2:24839960-24839960
4 ADCY3 NM_004036.5(ADCY3):c.2578-1G>A SNV Risk Factor
495046 rs1553333167 GRCh37: 2:25047406-25047406
GRCh38: 2:24824537-24824537
5 ADCY3 NM_004036.5(ADCY3):c.2433-1G>A SNV Risk Factor
495043 rs1331776405 GRCh37: 2:25050478-25050478
GRCh38: 2:24827609-24827609

Expression for Body Mass Index Quantitative Trait Locus 19

Search GEO for disease gene expression data for Body Mass Index Quantitative Trait Locus 19.

Pathways for Body Mass Index Quantitative Trait Locus 19

GO Terms for Body Mass Index Quantitative Trait Locus 19

Sources for Body Mass Index Quantitative Trait Locus 19

8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
27 GO
28 GTR
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
36 LifeMap
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....